Document is current

Article History

Received: 13 January 2025

Accepted: 2 April 2025

First Online: 12 May 2025

Competing interests

: S.B., R.A., D.C., R.S.G., R.P.G., A.M.K., X.L., A.Q., R.M., N.S., L.T., H.L.W., received hourly payment for participation on day 1 and day 2. S.B., J.R., H.S., received hourly payment for work on Gastric Cell Atlas. J.R. is a consultant for DLS (co-founder of Targos now part of DLS), Astellas, AstraZeneca, BMS, Daiichi Sankyo, GSK, Merck Sharp&Dohme, Merck KGaA and QUip and co-founder of Gnothis Inc. R.A. is a consultant for BMS, Merck SD, AstraZeneca and Jazz pharmaceuticals. S.B. is a scientific advisor to Mindpeak, an ad hoc advisor to AstraZeneca, Daiichi Sankyo, Ventana-Roche, a speaker for AstraZeneca, Daiichi Sankyo, Agilent (Dako), Ventana-Roche, Merck, BMS, a research funding recipient of NCI R01CA121932, Eli Lilly and Agilent (Dako), is a Susan G. Komen Scholar, and the Director of ICGA Foundation, India. R.A. is the recipient of research funding from BMS, RAPT pharmaceuticals, StandUp2Cancer, Breakthrough Cancer and the NIH. G.K., M.K., were employees and shareholders of BMS, when the study was conducted. M.K. is a scientific advisor to DLS, ReviveMed, PictureHealth and a Board Member of FT3. J.P. is an employee and shareholder of BMS. T.L., P.F., M.P., K.D., F.F. are employees and shareholders of Mindpeak. E.P. is an employee and shareholder of Augmentiqs Medical.